Clinical Trial Update: ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 trial of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone for relapsed and refractory multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)
• Ricolinostat (ACY-1215) (ricolinostat)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-03-04